Type
Business expansion
Country
Ireland
Region
Ireland; Eastern and Midland; Dublin
Location of affected unit(s)
Damastown (Dublin)
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

330 jobs
Number of planned job creations
Job creation
Announcement Date
31 March 2026
Employment effect (start)
1 January 2026
Foreseen end date
30 April 2026

Description

US-headquartered pharmaceutical multinational, West Pharmaceutical Services has created 330 new jobs as a result of opening of a major manufacturing expansion at its Damastown site in Dublin. Most of the roles have already been filled.

The new facility was officially launched in March 2026 and supports high volume production of drug delivery systems used in treatments for diabetes and obesity.

Public authorities were involved in welcoming the investment. IDA Ireland and the Minister for Public Expenditure, Infrastructure, Public Service Reform and Digitalisationwelcomed the opening of the new facility, describing it as beneficial for both the local community and the national life sciences sector.

The company employs more than 10,000 people in 50 global locations, including 1,400 in Ireland across sites in Dublin and Waterford. West said the investment strengthens its global manufacturing capacity and underlines Ireland’s role as a hub for advanced pharmaceutical and medtech production.


Sources

Citation

Eurofound (2026), West Pharmaceuticals, Business expansion in Ireland, factsheet number 204572, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/204572.